Can Apixaban (Eliquis) Cause a Positive Antiphospholipid IgM Test?
No, apixaban (Eliquis) does not cause a positive antiphospholipid IgM antibody test. Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa and does not induce the production of antiphospholipid antibodies 1.
Key Points About Anticoagulants and Antiphospholipid Testing
Direct Oral Anticoagulants Do Not Cause Positive aPL Antibodies
- Apixaban does not induce antiphospholipid antibodies of any isotype (IgG, IgM, or IgA) 1.
- The FDA-approved drug label for Eliquis lists no association between apixaban therapy and development of antiphospholipid antibodies 1.
- Anticardiolipin IgM and anti-β2-glycoprotein I IgM antibodies are measured by solid-phase assays (ELISA) that detect autoimmune antibodies, not drug effects 2.
Anticoagulants Can Interfere With Lupus Anticoagulant Testing (But Not Solid-Phase Assays)
- DOACs including apixaban interfere with lupus anticoagulant (LA) functional coagulation assays, producing unreliable results that may be falsely positive or negative 2, 3, 4.
- However, anticardiolipin and anti-β2-glycoprotein I antibody testing by ELISA is reliable during DOAC therapy because these solid-phase assays are not affected by anticoagulants 2.
- Vitamin K antagonists (warfarin) can also interfere with LA testing but do not affect anticardiolipin or anti-β2GPI antibody measurements 2.
What Actually Causes Positive Antiphospholipid IgM Antibodies
Common Causes of Transient aPL Positivity
- Acute infections commonly cause transient antiphospholipid antibody positivity, which is why confirmation testing at least 12 weeks apart is required for APS diagnosis 2, 3, 5.
- Certain medications can induce transient aPL production (though apixaban is not among them), requiring repeat testing after drug discontinuation 5.
- Drug-induced aPL typically resolve after medication cessation 5.
Persistent aPL Positivity
- Systemic lupus erythematosus (SLE) is the most common autoimmune disease associated with aPL, with approximately 37% of SLE patients testing positive 5.
- Primary antiphospholipid syndrome occurs when aPL are present without an underlying autoimmune disease 3, 4.
- Approximately 6% of pregnant women without diagnosed APS test positive for aPL 5.
Critical Testing Considerations
When to Suspect True APS vs. Transient Positivity
- Never diagnose APS on a single positive test; repeat testing after a minimum interval of 12 weeks is mandatory to exclude transient positivity 3, 4.
- If a patient on apixaban has a positive anticardiolipin IgM or anti-β2GPI IgM, the apixaban is not the cause—investigate other etiologies such as infection, autoimmune disease, or pregnancy 5.
Timing Pitfalls That Can Affect Results
- Performing antibody testing during an acute thrombotic event may yield falsely low anti-β2-glycoprotein I titers because antibodies can be sequestered at the clot site 3.
- During pregnancy, antiphospholipid antibody levels can fluctuate, with approximately 25% of lupus anticoagulant-positive patients becoming negative in the second or third trimester 3, 5.
Clinical Bottom Line
If your patient on apixaban has a positive antiphospholipid IgM test, the apixaban is not responsible. The positive result indicates either:
- Transient antibody positivity from infection or other causes—confirm with repeat testing in ≥12 weeks 2, 3, 4
- True antiphospholipid syndrome or underlying autoimmune disease 3, 5
- Laboratory interference (only if testing lupus anticoagulant, not if testing anticardiolipin or anti-β2GPI by ELISA) 2, 3
The presence of antiphospholipid antibodies in a patient taking apixaban should prompt evaluation for APS or other autoimmune conditions, not attribution to the medication 3, 5.